• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雷珠单抗(Lucentis)玻璃体内注射对眼内压的短期影响。

Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.

机构信息

Department of Ophthalmology, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia," Udine, Italy.

出版信息

J Glaucoma. 2009 Dec;18(9):658-61. doi: 10.1097/IJG.0b013e31819c4893.

DOI:10.1097/IJG.0b013e31819c4893
PMID:20010243
Abstract

PURPOSE

To investigate short-term effect on intraocular pressure (IOP) after intravitreal injection of ranibizumab (Lucentis) (IVIL).

MATERIALS AND METHODS

This prospective study included 1 eye of 54 patients (64+/-12 y) with wet age-related macular degeneration treated with IVIL. IOP measurements with TonoPen were taken: immediately before and 5 seconds, 5, 10, 15, 30, 60 minutes, and 1 day after IVIL. Axial length (with ultrasound biometry) was assessed in 24 eyes. The analysis included IOP difference at various time points and between phakic and pseudophakic eyes and the relationship between axial length and IOP increases after 5 seconds.

RESULTS

Mean IOP were 16.3+/-3.0 mm Hg (range: 12.0 to 21.3), 44.1+/-10.6 (22.0 to 59.3), 29.0+/-9.6 (15.0 to 49.0), 25.8+/-7.9 (16.0 to 45.0), 23.7+/-6.6 (15.7 to 39.0), 21.9+/-5.6 (14.7 to 37.0), 18.8+/-6.1 (10.0 to 35.0), and 16.1+/-3.0 (11.0 to 21.0), respectively, for time points immediately before, 5 seconds, 5, 10, 15, 30, 60 minutes, and 1 day after IVIL. Differences between before IVIL and after IVIL IOP were statistically significant after 5 seconds, 5, 10, 15, and 30 minutes (P=0.0001); however, were not significant after 1 hour (P=0.064) and 1 day (P=0.449). Differences between phakic and pseudophakic eyes were not significant (P>0.05). The relationship between shorter axial length and IOP increase after 5 seconds was significant (linear regression analysis; R=0.28, P=0.007).

CONCLUSIONS

IVIL causes a considerable short-term transient rise in IOP. The IOP increase after IVIL can be statistically significant at 0 to 30 minutes after injection in both phakic and pseudophakic eyes, and tends to be greater in shorter eyes.

摘要

目的

研究玻璃体内注射雷珠单抗(Lucentis)后对眼内压(IOP)的短期影响。

材料和方法

本前瞻性研究纳入了 54 例(64+/-12 岁)湿性年龄相关性黄斑变性患者的 1 只眼,均接受玻璃体内注射雷珠单抗治疗。使用 TonoPen 测量眼压:注射前即刻和注射后 5 秒、5、10、15、30、60 分钟和 1 天。在 24 只眼中评估眼轴长度(使用超声生物测量法)。分析包括不同时间点的眼压差异、有晶状体眼和无晶状体眼之间的差异以及注射后 5 秒时眼轴长度与眼压升高之间的关系。

结果

平均眼压分别为 16.3+/-3.0mmHg(范围:12.0 至 21.3)、44.1+/-10.6mmHg(22.0 至 59.3)、29.0+/-9.6mmHg(15.0 至 49.0)、25.8+/-7.9mmHg(16.0 至 45.0)、23.7+/-6.6mmHg(15.7 至 39.0)、21.9+/-5.6mmHg(14.7 至 37.0)、18.8+/-6.1mmHg(10.0 至 35.0)和 16.1+/-3.0mmHg(11.0 至 21.0),分别为注射前即刻、注射后 5 秒、5、10、15、30、60 分钟和 1 天的眼压。与注射前相比,注射后 5 秒、5、10、15 和 30 分钟时眼压差异有统计学意义(P=0.0001);然而,在 1 小时(P=0.064)和 1 天(P=0.449)时差异无统计学意义。有晶状体眼和无晶状体眼之间的差异无统计学意义(P>0.05)。5 秒时较短的眼轴长度与眼压升高之间的关系具有显著意义(线性回归分析;R=0.28,P=0.007)。

结论

玻璃体内注射雷珠单抗可导致明显的短期眼压一过性升高。在有晶状体眼和无晶状体眼中,注射后 0 至 30 分钟时眼压升高具有统计学意义,且在较短眼轴中更明显。

相似文献

1
Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.雷珠单抗(Lucentis)玻璃体内注射对眼内压的短期影响。
J Glaucoma. 2009 Dec;18(9):658-61. doi: 10.1097/IJG.0b013e31819c4893.
2
Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.溴莫尼定/噻吗洛尔固定复方制剂对预防玻璃体内注射雷珠单抗后短期眼压升高的作用。
Klin Monbl Augenheilkd. 2010 Apr;227(4):280-4. doi: 10.1055/s-0029-1245201. Epub 2010 Apr 20.
3
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.雷珠单抗(Lucentis)多次递增剂量治疗新生血管性年龄相关性黄斑变性的耐受性和疗效
Ophthalmology. 2006 Apr;113(4):623.e1. doi: 10.1016/j.ophtha.2006.01.027.
4
A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection.单次玻璃体内注射曲安奈德后早期眼压变化的前瞻性研究。
J Glaucoma. 2008 Mar;17(2):128-32. doi: 10.1097/IJG.0b013e31814b9948.
5
Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.玻璃体内注射雷珠单抗对眼轴长度和眼压的短期影响。
Cutan Ocul Toxicol. 2013 Mar;32(1):23-6. doi: 10.3109/15569527.2012.696569. Epub 2012 Jun 27.
6
Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.玻璃体内注射雷珠单抗可能会导致新生血管性年龄相关性黄斑变性患者的视网膜小动脉血管收缩。
Ophthalmology. 2009 Sep;116(9):1755-61. doi: 10.1016/j.ophtha.2009.03.017. Epub 2009 Jun 27.
7
Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).玻璃体内注射0.05毫升雷珠单抗(Lucentis)后的眼压变化过程。
Eur J Ophthalmol. 2010 Jan-Feb;20(1):174-9. doi: 10.1177/112067211002000124.
8
Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.玻璃体内注射曲安奈德后眼内压的短期变化过程
Ophthalmology. 2006 Jul;113(7):1174-8. doi: 10.1016/j.ophtha.2005.10.061. Epub 2006 May 2.
9
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.雷珠单抗治疗新生血管性年龄相关性黄斑变性:一项I/II期多中心、对照、多剂量研究。
Ophthalmology. 2006 Apr;113(4):633.e1-4. doi: 10.1016/j.ophtha.2005.10.052. Epub 2006 Feb 14.
10
Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.玻璃体内注射曲安奈德所致的眼压升高与后囊下白内障的发生有关。
Ophthalmology. 2005 Jan;112(1):139-43. doi: 10.1016/j.ophtha.2004.07.017.

引用本文的文献

1
Intraocular Pressure After Anti-Vascular Endothelial Growth Factor Injection in Eyes With a Mineralized Bruch's Membrane Caused by Pseudoxanthoma Elasticum.弹性假黄瘤所致矿化布鲁赫膜眼内抗血管内皮生长因子注射后的眼压
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):25. doi: 10.1167/iovs.66.11.25.
2
Intraocular Pressure Changes following Intravitreal Topotecan 90 μg/0.18 cc for the Treatment of Retinoblastoma.玻璃体内注射90μg/0.18cc拓扑替康治疗视网膜母细胞瘤后的眼压变化
Ocul Oncol Pathol. 2025 Jun 5. doi: 10.1159/000546729.
3
Effects of anti‑VEGF on peripapillary retinal nerve fiber layer and papillary/peripapillary blood circulation in retinopathies (Review).
抗血管内皮生长因子对视网膜病变中视乳头周围视网膜神经纤维层及视乳头/视乳头周围血液循环的影响(综述)
Int J Mol Med. 2025 Sep;56(3). doi: 10.3892/ijmm.2025.5574. Epub 2025 Jul 4.
4
Comparison of intraocular pressure elevation following intravitreal injection of 70 µl aflibercept 8 mg.玻璃体内注射70微升8毫克阿柏西普后眼压升高的比较
Jpn J Ophthalmol. 2025 Jun 26. doi: 10.1007/s10384-025-01239-7.
5
Contributing factors to short-term intraocular pressure elevation following intravitreal anti-VEGF injections.玻璃体内注射抗血管内皮生长因子药物后短期眼压升高的相关因素。
BMC Ophthalmol. 2025 May 7;25(1):281. doi: 10.1186/s12886-025-04111-x.
6
Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes after Intravitreal Anti-Vascular Endothelial Growth Factors Injection.估计的个体玻璃体体积对玻璃体内注射抗血管内皮生长因子后眼压峰值的影响。
Ophthalmic Res. 2025;68(1):108-116. doi: 10.1159/000543071. Epub 2024 Dec 18.
7
Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections.降低眼压药物预防玻璃体内抗血管内皮生长因子注射后眼压峰值的随机临床试验
Ophthalmol Ther. 2025 Feb;14(2):351-362. doi: 10.1007/s40123-024-01081-z. Epub 2024 Dec 18.
8
Evaluation of Sustained Intraocular Pressure Elevations Across Antivascular Endothelial Growth Factor Agents.抗血管内皮生长因子药物引起的眼内压持续升高的评估
J Vitreoretin Dis. 2024 Dec 13:24741264241304813. doi: 10.1177/24741264241304813.
9
The Effect of Dorzolamide-timolol Eye drop on Intraocular Pressure Change in Intravitreal Ranibizumab Injected Patients.多佐胺-噻吗洛尔滴眼液对玻璃体内注射雷珠单抗患者眼压变化的影响。
Middle East Afr J Ophthalmol. 2024 Jun 14;30(2):85-88. doi: 10.4103/meajo.meajo_177_23. eCollection 2023 Apr-Jun.
10
Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes.背景疾病及既往玻璃体内注射阿柏西普的次数对有晶状体眼即时眼压升高和玻璃体反流率的影响
Int J Ophthalmol. 2024 Mar 18;17(3):545-550. doi: 10.18240/ijo.2024.03.17. eCollection 2024.